Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about GDTC, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Human Umbilical Cord derived MSCs | Lupus Nephritis | Phase 2 · NCT01539902 | Unknown |
| Adoptive Cell Transfer of NKG2DL-targetting… | Colorectal Cancer | Phase 1 · NCT04107142 | Unknown |
| Allogeneic NKG2DL-targeting Chimeric Antigen… | Cancer | Phase 1 · NCT05302037 | Recruiting |
| human Mesenchymal Stem Cell (MSC) infusion… | Aging Well | Phase 1 · NCT04174898 | Unknown |
Also used in these trials (approved or third-party drugs, not GDTC's own candidates): Cyclophosphamide.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
GDTC holds $1.5M in cash and short-term investments and burns about $936,010/quarter from operations, an estimated runway of 4.7 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 65 · High
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when GDTC files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| Chee Kong Choo Director, 10% owner |
Insider | 3,003,996 | 25.40% | 2026-10-12 |
| mDR LTD | 5%+ holder (13G) | 1,191,523 | 10.07% | 2026-10-12 |
| Yoong Ying Tan Chief Corporate Officer |
Insider | 25,781 | 0.22% | 2026-03-18 |
| Yvonne Goh Chief Financial Officer |
Insider | 25,781 | 0.22% | 2026-03-18 |
| Keng Kiat Toh Director |
Insider | 4,000 | 0.03% | 2026-03-18 |
| Chak Hua Yew Director |
Insider | 2,469 | 0.02% | 2026-03-18 |
Share count 11,828,435 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for GDTC and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →